Natalia Roson-Calero

Ms. Natalia Roson-Calero

Pre-doctoral Student
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
JMJayaseelan Murugaiyan
Jayaseelan Murugaiyan
APAnand Kumar P
Anand Kumar P
GRG. Srinivasa Rao
G. Srinivasa Rao
Katia ISKANDARKatia ISKANDAR
Katia ISKANDAR
SHStephen Hawser
Stephen Hawser
MDMaarten van Dongen
Maarten van Dongen
Antibiotic resistance, and, in a broader perspective, antimicrobial resistance (AMR), continues to evolve and spread beyond all boundaries. As a result, infectious diseases have become more challenging or even impossible to treat, leading to an increase in morbidity and mortality. Despite the failure of conventional, traditional antimicrobial therapy, in the past two decades, no novel class of antibiotics has been introduced. Consequently, several novel alternative strategies to combat these (multi-) drug-resistant infectious microorganisms have been identified. The purpose of this review is to gather and consider the strategies that are being applied or proposed as potential alternatives to traditional antibiotics. These strategies include combination therapy, techniques that target the enzymes or proteins responsible for antimicrobial resistance, resistant bacteria, drug delivery systems, physicochemical methods, and unconventional techniques, including the CRISPR-Cas system. These alternative strategies may have the potential to change the treatment of multi-drug-resistant pathogens in human clinical settings.

19 June 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
NRNatalia Roson-Calero
Natalia Roson-Calero
Clara Balleste-DelpierreClara Balleste-Delpierre
Clara Balleste-Delpierre
JFJavier Fernández
Javier Fernández
Jordi VilaJordi Vila
Jordi Vila
In the last decades, we have witnessed a steady increase in infections caused by multidrug-resistant (MDR) bacteria. These infections are associated with higher morbidity and mortality. Several interventions should be taken to reduce the emergence and spread of MDR bacteria. The eradication of resistant pathogens colonizing specific human body sites that would likely cause further infection in other sites is one of the most conventional strategies. The objective of this narrative mini-review is to compile and discuss different strategies for the eradication of MDR bacteria from gut microbiota. Here, we analyse the prevalence of MDR bacteria in the community and the hospital and the clinical impact of gut microbiota colonisation with MDR bacteria. Then, several strategies to eliminate MDR bacteria from gut microbiota are described and include: (i) selective decontamination of the digestive tract (SDD) using a cocktail of antibiotics; (ii) the use of pre and probiotics; (iii) fecal microbiota transplantation; (iv) the use of specific phages; (v) engineered CRISPR-Cas Systems. This review intends to provide a state-of-the-art of the most relevant strategies to eradicate MDR bacteria from gut microbiota currently being investigated.

1 December 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
NRNatalia Roson-Calero
Natalia Roson-Calero
JLJimmy Lucas
Jimmy Lucas
MGMaría A. Gomis-Font
María A. Gomis-Font
RJRoger de Pedro Jove
Roger de Pedro Jove
AOAntonio Oliver
Antonio Oliver
Jordi VilaJordi Vila
Jordi Vila
Background/Objectives: Acinetobacter baumannii is a globally emerging pathogen with widespread antimicrobial resistance driven by multiple mechanisms, such as altered expression of efflux pumps like AdeABC, placing it as a priority for research. Driven by the lack of new treatments, alternative approaches are being explored to combat its infections, among which efficacy-enhancing adjuvants can be found. This study presents and characterizes MV6, a synthetic cyclic peptide that boosts aminoglycoside efficacy. Methods: MV6’s activity was assessed through antimicrobial susceptibility testing in combination with different antibiotic classes against A. baumannii strains characterized by PCR and RT-qPCR. PAβN served as a reference efflux pump inhibitor. Synergy was evaluated using checkerboard assays, and spontaneous mutants were generated with netilmicin with/without MV6 (100 mg/L). Whole-genome sequencing and variant calling analysis were then performed. Results: MV6 presented low antimicrobial activity in A. baumannii with MICs higher than 2048 mg/L. MV6 showed a better boosting effect for aminoglycosides, especially netilmicin, exceeding that of PAβN. Checkerboard assays confirmed a strong synergy between netilmicin and MV6, and a significant correlation was found between netilmicin MIC and adeB overexpression, which was mitigated by the presence of MV6. MV6 reduced, by 16-fold, the mutant prevention concentration of netilmicin. Mutations in a TetR-family regulator and ABC-binding proteins were found in both groups, suggesting a direct or indirect implication of these proteins in the resistance acquisition process. Conclusions: MV6 lacks intrinsic antimicrobial activity, minimizing selective pressure, yet enhances netilmicin’s effectiveness except for strain 210, which lacks the AdeABC efflux pump. Resistant mutants indicate specific aminoglycoside resistance mechanisms involving efflux pump mutations, suggesting synergistic interactions. Further research, including transcriptomic analysis, is essential to elucidate MV6’s role in enhancing netilmicin efficacy and its resistance mechanisms.

13 February 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
NRNatalia Roson-Calero
Natalia Roson-Calero
MFMaría A. Gomis Font
María A. Gomis Font
ARAlbert Ruiz-Soriano
Albert Ruiz-Soriano
XJXavier Just-Baringo
Xavier Just-Baringo
MPMaría Eugenia Pachón-Ibáñez
María Eugenia Pachón-Ibáñez
Jordi VilaJordi Vila
Jordi Vila
The pipeline for new drugs against multidrug-resistant Pseudomonas aeruginosa remains limited, highlighting the urgent need for innovative treatments. New strategies, such as membrane-targeting molecules acting as adjuvants, aim to enhance antibiotic effectiveness and combat resistance. RW01, a cyclic peptide with low antimicrobial activity, was selected as an adjuvant to enhance drug efficacy through membrane permeabilization. RW01’s activity was evaluated via antimicrobial susceptibility testing in combination with existing antibiotics on 10 P. aeruginosa strains and analog synthesis. Synergy was assessed using checkerboard assays, and one-step mutants were generated to identify altered pathways through whole-genome sequencing and variant analysis. Permeabilizing activity was studied using flow cytometry and real-time fluorescence measurement. In vivo toxicity was assessed in female C57BL/6J mice, and possible interaction with mouse serum was also evaluated. Susceptibility testing revealed specific synergy with tetracyclines, with up to a 16-fold reduction in minimum inhibitory concentrations. Sequencing revealed that resistance to the RW01-minocycline combination involved mutations in the pmrB gene, affecting outer membrane lipopolysaccharide composition. This was further confirmed by the identification of cross-resistance to colistin in these mutants. RW01 reduced the mutant prevention concentration of minocycline from 64 to 8 mg/L. RW01 was demonstrated to enhance membrane permeabilization and therefore minocycline uptake with statistical significance. Synthetic derivatives of RW01 showed a complete loss of activity, highlighting the importance of RW01’s D-proline(NH2) residue. No acute or cumulative in vivo toxicity was observed in mice. These findings suggest that RW01 could revitalize obsolete antimicrobials and potentially expand therapeutic options against multidrug-resistant P. aeruginosa .

27 September 2025 in Discover Geoscience
Verified
Journal Article
Open access
PDF file
Eulyn PagalingEulyn Pagaling
Eulyn Pagaling
JPJavier Palarea-Albaladejo
Javier Palarea-Albaladejo
STSara Trojahn
Sara Trojahn
NRNatalia Roson-Calero
Natalia Roson-Calero
SGSheila Gibbs
Sheila Gibbs
Miriam GlendellMiriam Glendell
Miriam Glendell
Antimicrobial resistance (AMR) is a global public health threat as it reduces the effectiveness of drug treatments and therefore our ability to combat infections. For the first time, this study used high temporal resolution data of antimicrobial resistance genes (ARG) in two livestock-dominated agricultural study catchments in south-west Scotland to understand ‘background’ ARG loadings in the absence of pollution point-sources such as sewage treatment works and health care facilities. Daily composite samples were collected twice a week over a 2-year period 2017–2019, resulting in 124 samples in Cessnock (22 km2) and 93 in the Mein (12 km2) catchment. We found a seasonal pattern in ARG relative abundance, with highest abundance in winter inversely related to the highest bacterial abundance in summer. This could reflect seasonal input from faecal pollution during winter high flows, indicated by a relationship between E. coli and terrestrial dissolved organic matter (DOM) sources. However, faecal indicator organisms (FIOs) ranked as less important predictors, so the seasonal pattern could be caused by microbial stress during cold periods and/or competition with susceptible bacteria during the warm periods. These natural fluctuations need to be considered when inferring potential drivers of AMR prevalence in surface waters. Therefore, in future monitoring, we recommend higher temporal resolution and longer-term monitoring (at least one year) to improve our understanding of natural seasonal variation in ARG abundance and evaluate effectiveness of mitigation measures (e.g., waste management).